2025年5月份，新华.中盐两碱工业盐价格指数报947.78点，较上期(2025年4月)下跌15.96点，跌幅 1.66%；较基期(2018年1月)下跌52.22点，跌幅5.22%；较周期内最高点1736.66点(2022年4月)下跌788.88 点，跌幅4.43%；较周期内最低点816.2点(2020年8月)上涨131.58点，涨幅16.12%。 分区域来看，2025年5月，安徽、江苏、重庆、云南两碱工业盐出厂价格较2025年4月上涨；湖北、湖 南、四川、辽宁两碱工业盐出厂价格较2025年4月持平；陕西、江西、河南、新疆、河北、山东、天津 两碱工业盐出厂价格较2025年4月下跌。 分价格区间来看，本期两碱工业盐单价在300元／吨及以上的地区有3个，分别是河南、云南、辽宁；两 碱工业盐单价在300元／吨以下的地区有14个，分别是陕西、安徽、江苏、湖北、江西、重庆、新疆、 河北、山东、湖南、青海、四川、天津、宁夏。 5月份我国原盐市场呈现供应增长而需求平稳态势。五一假期结束，多地持续开展密集扒盐产盐工作， 月内海盐市场供应量显著上升，特别是河北、山东、江苏等主产区的产量增长明显。然而，下游碱企采 购需求跟进有限 ...

Core Viewpoint - Yunnan Energy Investment (002053.SZ) is significantly expanding its wind power business by securing development rights for three wind farms, totaling an expected installed capacity of 312.5 MW, with a project completion timeline of 12 months [1][2]. Group 1: Project Development - The company has been awarded the development rights for three wind farms: the South Chong Wind Farm in Fuyuan, the Aguzai Wind Farm in Lijiang, and the Huaping West Wind Farm in Lijiang, with respective capacities of approximately 62.5 MW, 100 MW, and 150 MW [2]. - The project sites are noted for their favorable wind conditions, and the total construction period for all projects is estimated to be 12 months [2]. Group 2: Business Transformation - Yunnan Energy Investment, originally Yunnan Salt Chemical, transitioned into the renewable energy sector in 2019 by acquiring shares in a wind power company from its major shareholder, marking a strategic shift towards new energy development [1][4]. - The company aims to enhance its renewable energy capabilities, focusing on wind and solar power, which accounted for 34.45% of its total revenue in 2024 [4]. Group 3: Financial Performance - The company has experienced continuous growth in revenue and net profit over the past four years, with revenues increasing from 23.48 billion yuan in 2021 to 34.53 billion yuan in 2024, and net profits rising from 2.49 billion yuan to 6.75 billion yuan in the same period [5]. - In the first quarter of 2025, Yunnan Energy Investment reported total revenue of 9.54 billion yuan and a net profit of 2.21 billion yuan, reflecting ongoing growth in its asset scale, which reached 187.95 billion yuan by the end of Q1 2025 [6]. Group 4: Diversified Operations - Besides its renewable energy initiatives, the company is also involved in salt production and natural gas operations, with salt products generating 12 billion yuan in revenue in 2024, accounting for 34.86% of total revenue [6]. - The company is implementing a project to upgrade its salt production facility using energy-efficient technology, with a total investment of 448 million yuan [6].

Core Viewpoint - The company, Lianbang Pharmaceutical, has shown significant progress in its drug development, particularly in weight loss and insulin products, while maintaining a stable growth outlook in its antibiotic and animal health segments [1][2][3] Group 1: Weight Loss Drug Development - UBT251 has achieved authorization, and the clinical trial results for UBT251 in China show a 15.1% average weight loss from baseline at the highest dose after 12 weeks, compared to a 1.5% increase in the placebo group [1] - The safety profile of UBT251 is similar to other gut incretin products, with the most common adverse events being gastrointestinal reactions, mostly mild to moderate [1] - The company has granted overseas rights for UBT251 to Novo Nordisk, receiving an upfront payment of $200 million and potential milestone payments of up to $1.8 billion, along with tiered sales royalties based on annual net sales in overseas regions [1] Group 2: Insulin Business Outlook - The company has successfully won bids in all six procurement groups for insulin, with all selected products classified as Class A, indicating a stable growth outlook for its insulin business [2] - The company’s self-production costs are controllable, which supports the expectation of stable growth in the insulin segment [2] Group 3: Animal Health and Antibiotics - The company anticipates that 19 animal health formulations will be launched by 2025, with over 10 formulations expected to be approved annually from 2026 to 2028, indicating a strong pipeline and growth potential in the animal health market [2] - The company has established itself as a leader in the penicillin industry, with a market share of around 50% in both penicillin industrial salt and 6-APA, benefiting from vertical integration and process iteration [2] - The antibiotic business is expected to remain stable, despite some anticipated fluctuations in demand starting in Q4 2024, due to the execution of centralized procurement for piperacillin-tazobactam sodium [2] Group 4: Financial Projections and Valuation - The company’s projected total revenue for 2025-2027 is estimated at 145.24 billion, 139.87 billion, and 145.80 billion yuan, with year-on-year growth rates of 5.56%, -3.70%, and 4.23% respectively [2] - The projected net profit attributable to the parent company for the same period is 29.07 billion, 25.57 billion, and 27.62 billion yuan [2] - The company is valued using a comparable company valuation method, with a target market capitalization of 34.102 billion HKD and a target price of 18.77 HKD per share, reflecting a buy rating [3]

证券代码：601065 证券简称：江盐集团 公告编号：2025-015 江西省盐业集团股份有限公司 2024 年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江西省盐业集团股份有限公司（以下简称"公司"）根据上海证券交易所《上 市公司行业信息披露指引第十三号——化工》有关规定，现将 2024 年度主要经 营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | | 产量（万吨） | | 销量（万吨） | 营业收入 | | --- | --- | --- | --- | --- | --- | | | 报告期 | 同期 | 报告期 | 同期 | （万元） | | 食盐 | 61.11 | 57.79 | 60.90 | 57.52 | 44,492.44 | | 工业盐 | 246.96 | 217.10 | 241.81 | 216.95 | 82,979.76 | | 元明粉 | 0.42 | 7.23 | 0.50 | 7.57 | 199.78 | | 氯化钙 | 15.78 | ...

证券代码：601065 证券简称：江盐集团 公告编号：2025-016 江西省盐业集团股份有限公司 2025 年第一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江西省盐业集团股份有限公司（以下简称"公司"）根据上海证券交易所《上 市公司行业信息披露指引第十三号——化工》有关规定，现将 2025 年第一季度 主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | | 产量（万吨） | | 销量（万吨） | 营业收入 （万元） | | --- | --- | --- | --- | --- | --- | | | 报告期 | 同期 | 报告期 | 同期 | | | 食盐 | 14.17 | 13.85 | 13.79 | 13.07 | 9,071.46 | | 工业盐 | 63.09 | 54.47 | 64.66 | 49.60 | 18,975.86 | | 氯化钙 | 5.87 | 3.55 | 2.94 | 2.11 | 1,824.32 | | 纯碱 | 19.39 ...

证券代码：600141 证券简称：兴发集团 公告编号：临2025-029 转债代码：110089 转债简称：兴发转债 湖北兴发化工集团股份有限公司 2025 年第一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第十三号——化工 （2022 年修订）》的要求，湖北兴发化工集团股份有限公司（以下简称"公 司"）现将2025 年第一季度主要经营数据披露如下： 注：1.特种化学品主要包括电子化学品、食品添加剂以及用于油田、水处理、医药等领域的其它精细 化学品和助剂，下同；2.农药产品包括草甘膦原药与制剂、百草枯原药与制剂、2,4-滴、烟嘧磺隆、咪草 烟原药等，下同；3.肥料包括磷酸一铵、磷酸二铵及复合肥产品，下同；4.有机硅系列产品包括DMC 及下 游深加工产品，下同。 主要产品 2025 年1 至3 月产量 （万吨） 2025 年1至3月销量 （万吨） 2025 年1 至3 月销售金额 （万元） 特种化学品 12.04 13.18 129,343.27 农药 ...

| 产品类别 | 报告期营业收入（单位：万元） | | --- | --- | | 食盐 | 16,064.70 | | 工业盐 | 17,552.19 | | 溴素 | 815.80 | 证券代码：600784 证券简称：鲁银投资 编号：2025-020 鲁银投资集团股份有限公司 2025 年一季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号行业信息披 露第十四号食品制造》的要求，公司现将 2025 年一季度主要经营数 据披露如下： 一、公司 2025 年一季度主要经营情况 1.按照产品类别分类情况 以上经营数据信息来源于公司报告期内财务数据，仅为投资者及 时了解公司生产经营情况之用，敬请广大投资者理性投资，注意投资 风险。 特此公告。 鲁银投资集团股份有限公司董事会 2025 年 4 月 28 日 2.按照销售渠道分类情况 | 销售渠道 | 报告期营业收入（单位：万元） | | --- | --- | | 直销 | 20,369.48 | | ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和 完整性承担法律责任。 证券代码：603213 证券简称：镇洋发展 公告编号：2025-024 转债代码：113681 转债简称：镇洋转债 浙江镇洋发展股份有限公司 关于 2025 年第一季度主要经营数据的公告 注：氯碱类产品包括：烧碱、液氯、次氯酸钠、氯化石蜡和环氧氯丙烷等； MIBK类产品包括：甲基异丁基酮、二异丁基酮等；PVC类产品包含聚氯乙烯、盐酸3 等。 二、主要产品的价格变动情况（不含税） 单位：元/吨 | 主要产品 | 2025年第一季度均 | 2024年第一季度均 | 变动幅度（%） | | --- | --- | --- | --- | | | 价 | 价 | | | 氯碱类产品 | 1,864.53 | 1,652.16 | 12.85 | | 其中：烧碱 | 3,043.76 | 2,632.36 | 15.63 | | MIBK类产品 | 8,112.90 | 12,136.24 | -33.15 | | PVC类产品 | 3,948.06 | - | - | 浙江镇洋发展股份 ...

Core Viewpoint - Yunnan Energy Investment (云南能投) reported a decline in revenue and net profit for Q1 2025, while actively pursuing growth in its renewable energy sector and optimizing resource allocation through strategic investments [2][5]. Financial Performance - In Q1 2025, the company achieved operating revenue of 954 million yuan, a year-on-year decrease of 2.12% - The net profit attributable to shareholders was 221 million yuan, down 38.03% year-on-year - The net cash flow from operating activities was 243 million yuan, indicating overall good financial performance despite the decline in profits [2][5]. Business Strategy - The company is focusing on enhancing its core business in renewable energy by advancing projects and increasing resource acquisition - A significant investment was made in Yunnan Province's natural gas subsidiary, which will no longer be included in the consolidated financial statements, allowing the company to concentrate on its renewable energy initiatives [2][4]. Renewable Energy Development - Yunnan Province has made significant progress in clean energy trading since initiating market reforms in 2014, positioning the company to capitalize on these developments - The company aims to increase its market share in renewable energy, with 93.26% of its total electricity generation participating in market transactions in 2024 [3][4]. Project Pipeline - The company is actively working on the construction of 670,000 kW wind power expansion projects and several solar power projects, aiming for early completion and operation [3][4]. Market Conditions - The market price for clean energy in Yunnan has seen a slight decline due to increased supply and insufficient system adjustment capacity, but this is expected to improve with the introduction of energy storage projects [3][4]. Institutional Ratings - In the last 90 days, two institutions have rated the stock as a buy, with a target price averaging 16.32 yuan [5][6].

| 项目 | 2025 年第一季度 | | 2024 年第一季度 | 价格变动情况（%） | | --- | --- | --- | --- | --- | | | 平均销售价格 | | 平均销售价格 | | | | （元/吨） | | （元/吨） | | | 主要农药原药 | | 32,049.35 | 28,218.52 | 13.58 | | 主要农药中间体 | | 2,093.47 | 2,929.28 | -28.53 | 三、主要原材料价格波动情况（不含税） 证券代码：603599 证券简称：广信股份 编号：2025-013 安徽广信农化股份有限公司 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏并 对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上市公司行业信息披露指引第十八号—化工》、《关于 做好上市公司 2025 年第一季度报告披露工作的通知》的要求，安徽广信农化股 份有限公司（以下简称"公司"）现将 2025 年第一季度主要经营数据披露如下： 二、主要产品价格变动情况（不含税） | 项目 | ...